Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALDVI.PA
- Price
- 1.63
- Stock movement up
- +0.03 (1.87%)
- Company name
- Advicenne
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 20.05M
- Ent value
- 43.46M
- Price/Sales
- 6.01
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 2.49
- PEG
- -
- EPS growth
- 1.88%
- 1 year return
- -6.53%
- 3 year return
- -29.75%
- 5 year return
- -27.08%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
ALDVI.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.01 |
| Price to Book | - |
| EV to Sales | 13.04 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 12.28M |
| EPS (TTM) | -0.72 |
| FCF per share (TTM) | -0.68 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.33M |
| Gross profit (TTM) | 1.11M |
| Operating income (TTM) | -8.29M |
| Net income (TTM) | -8.83M |
| EPS (TTM) | -0.72 |
| EPS (1y forward) | 0.66 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 33.33% |
| Operating margin (TTM) | -248.83% |
| Profit margin (TTM) | -264.93% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.97M |
| Net receivables | 1.85M |
| Total current assets | 6.46M |
| Goodwill | 0.00 |
| Intangible assets | 267.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 7.97M |
| Accounts payable | 1.32M |
| Short/Current long term debt | 17.80M |
| Total current liabilities | 18.15M |
| Total liabilities | 25.39M |
| Shareholder's equity | -17.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -6.25M |
| Capital expenditures (TTM) | 692.00K |
| Free cash flow (TTM) | -8.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -110.80% |
| Return on Invested Capital | 145.66% |
| Cash Return on Invested Capital | 138.73% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.61 |
| Daily high | 1.63 |
| Daily low | 1.58 |
| Daily Volume | 17K |
| All-time high | 15.27 |
| 1y analyst estimate | 5.25 |
| Beta | 1.11 |
| EPS (TTM) | -0.72 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 14 May 2025 |
Downside potential
Loading...
Downside potential data
| ALDVI.PA | S&P500 | |
| Current price drop from All-time high | -89.31% | -12.89% |
| Highest price drop | -94.21% | -56.47% |
| Date of highest drop | 26 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -50.93% | -11.07% |
| Avg time to new high | 470 days | 12 days |
| Max time to new high | 1068 days | 1805 days |
COMPANY DETAILS
Marketcap
20.05M
Marketcap category
Small-cap
Description
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Employees
21
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
PARIS, March 27, 2025--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treat...
March 27, 2025
PARIS, November 28, 2024--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative t...
November 28, 2024